Merck brings Harpoon Therapeutics and its PhI/II T cell engager into the fold for $680M
Merck has struck a deal to buy Harpoon Therapeutics for $680 million, beefing up its oncology pipeline with a portfolio of T cell engagers.
At $23 per share, Merck’s offer comes in at a 100%-plus premium to Harpoon’s closing stock price on Friday. Harpoon’s share price $HARP rose after Bloomberg reported about the deal talks on Sunday and is up by 112% to $22.41 Monday morning following the deal announcement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.